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Purpose: To formulate simvastatin orodispersible tablets with high dissolution rate and enhanced 
bioavailability.  
Methods: Simvastatin solid dispersions in β- cyclodextrin, hydroxylpropyl-β-cyclodextrin, and 
hydroxylbutyl-β-cyclodextrin were prepared in different drug: polymer ratios by kneading and solvent 
evaporation methods. Compatibility was investigated by Differential scanning calorimetry (DSC) and 
Fourier transform infrared spectroscopy (FTIR) Based on the results of solubility studies, the most 
suitable solid dispersion was selected and formulated into orodispersible tablets using Emcosoy and K-
polacrillin as superdisintegrants, and mannitol and Pullulan as diluents. The tablets were evaluated for 
wetting and disintegration times, water absorption, and in vtro dissolution. 
Results: Increase in drug solubility was dependent on polymer type, concentration and preparation 
method. Simvastatin-hydroxylbutyl-β-cyclodextrin solid dispersion mixture prepared in 1:2 drug: polymer 
ratio by solvent evaporation method had a higher solubility than other dispersions. DSC and FTIR 
indicated the formation of solid dispersion without chemical interaction  between simvastatin and 
polymer. Orodispersible tablet prepared with Emcosoy and Pullulan showed least wetting and 
disintegration times (20 and 35 s, respectively), fastest water sorption rate, and the highest dissolution 
rate (100 % after 20 min).  
Conclusion: Orodispersible tablets prepared with Emcosoy as superdisintegratnt and Pullulan as 
diluents and containig simvastatin solid dispersion in hydroxylbutyl-β-cyclodextrin provides optimum 
water solubility and hence, drug bioavailability. 
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Oral route is the simplest and most convenient 
way of drug administration, with potential 
manufacturing cost savings [1]. Orally 
disintegrating systems are dosage forms, which 
when placed in the mouth, rapidly disperse or 
dissolve in saliva without the need of water or 
chewing and can be swallowed in the form of 
liquid [2]. After disintegration, the drug solution 
can be partially or completely absorbed from the 
sublingual mucosal blood vessels and bypasses 
the first pass metabolism of the liver [3], or be 
absorbed from the gastrointestinal tract after 
swallowing [4].  
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Simvastatin is widely used in the treatment of 
dyslipidemia as an adjunct to diet. It acts by  
specific inhibition of 3-hydroxy-3-methyl-glutaryl 
coenzyme-A (HMG CoA) reductase. It is 
practically water insoluble crystalline compound 
(BCS Class II drug) and the dissolution is the 
rate-limiting step that controls its oral absorption. 
Therefore, improvement in solubility and 
dissolution rate is essential to enhance drug 
bioavailability [5].  
 
Solid dispersion is a technique that depends on 
melting or dissolution process to disperse one or 
more active ingredients in a carrier or matrix in 
the solid state [6]. This ensures increased drug 
wettability, and the reduction of particle 
aggregation and hence increased drug 
dissolution [7]. Cyclodextrins (CDs) are cyclic α-
1,4 linked oligosaccharides of α -D-
glucopyranose units that have a relatively 
hydrophobic central cavity and hydrophilic outer 
surface [8]. CDs are classical examples of 
compounds that form stable inclusion complexes 
with a guest molecule [9]. 
 
Emcosoy is natural soy polysaccarides, that have 
no starch or any sugar and contains 75 % dietary 
fiber. In tablet manufacture; it had evidence of a 
fast and efficient disintegration power over an 
extended range of hardness values with 
improved dissolution characteristics. Polacrillin 
Potassium is a derivative of crosslinked polymer 
of polycarboxylic acids. In contact with aqueous 
media; it shows a very high swelling power 
leading to a very fast disintegration without the 
formation of lumps. 
 
In the present investigation simvastatin solid 
dispersions in cyclodextrins were prepared and 
optimized by different techniques, the solid 
dispersions were formulated into orodispersible 
tablet, using emcosoy and potassium polacrillin 
as superdisintegrants and evaluated in order to 







Simvastatin was Kindly supplied by (Saja 
Pharmaceuticals Co. Ltd., Jeddah, Saudi 
Arabia). β-cyclodextrins (β-CD), hydroxylpropyl-
β-cyclodextrins (H-p-β-CD), and hydroxylbutyl-β-
cyclodextrins (H-b-β-CD) were kindly supplied by 
(Nihon Shukohin Kako Co., Ltd., Japan). Pullulan 
(DMV International, Veghel, The Netherlands). 
Emcosoy (RS PHARMA GmbH & Co. KG 
Rosenberg Germany). Polacrillin Potassium 
(Libraw Pharma, New Delhi, India), Mannitol 
(Merck, Darmstadt, Germany), Saccharine 
Sodium from Caesar and Loretz (Hilden, 
Germany) and Aerosil  from Degussa 
(Frankfurt/M., Germany). Other chemicals and 
reagent were purchased from Sigma-Aldrich (St 
Louis, MO). 
 
Preparation of simvastatin solid dispersion 
 
Solid dispersions of simvastatin in β-CD, H-p-β-
CD, and H-b-β-CD were prepared by kneading, 
and solvent evaporation methods as follows:  
 
Solvent evaporation method  
 
Drug and polymer were mixed in the ratios (1:1, 
1:2, and 1:3) in a glass mortar methanol was 
added portion-wise with constant continuous 
stirring until the mixture completely dissolved. 
Methanol was evaporated under reduced 





In a glass mortar, 50% ethanol solution was 
added portion wise to the calculated polymer 
amount according to the selected drug/polymer 
ratio with trituration until a slurry like consistency 
was obtained. The drug was incorporated into 
the slurry and trituration was further continued for 
1 h, air dried at 25 oC for 48 h and the resulting 
dried product was pulverized and passed through 




Excess samples of plain simvastatin and the 
drug-solid dispersions were separately shaken 
for 48 h in 5 ml water at room temperature. 
Subsequently, the suspension was centrifuged at 
15000 rpm for 30 min and 1 ml filtrate diluted 
properly with methanol. The diluted solutions 
were spectrophotometrically analyzed at 238 nm. 
 
Evaluation of solid dispersion 
 
Based on the results of solubility studies, the 
solid dispersion mixture showing superior 
solubility was selected and subjected to further 
evaluation by DSC and FTIR, and for drug 
content and in vitro release. 
 
Differential scanning calorimetry (DSC) 
 
DSC thermograms for samples of plain 
simvastatin, H-b-β-CD, their physical mixture, 
and solid dispersion were recorded and 
analyzed. Approximately, 2 mg of samples were 
weighed into DSC aluminum pans and were 
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crimped followed by heating under nitrogen flow 
(20 ml/min) at a heating rate 10°C/min from 40 - 
400°C. Aluminum pan containing the same 
quantity of indium was used as a reference. DSC 
studies were carried out using DSC instrument 
(DSC-60, having TA60 software, Shimadzu, 
Koyto, Japan. 
 
Infrared spectroscopy (FTIR) 
 
Drug and various polymers were thoroughly 
mixed with 300 mg of potassium bromide, 
compressed to a 2 mm semitransparent disk and 
placed in the light path for 2 min. The FTIR 
spectra were recorded over the wave length 
range from 400 to 4000 cm-1 using FTIR 
spectrometer (Perkin Elmer Spectrum One, 
Model 16 PC, Germany). Drug content 
A pre-weighed quantity (10 mg) of the prepared 
solid dispersion was extracted into methanol and 
filtered (0.22 mm membrane filter disc - Millipore 
Corporation). The solid dispersion content was 
determined by measuring absorbance at 238 nm. 
 
In vitro release studies  
 
The drug release rate from the solid dispersion 
was carried out in Erweka-USP dissolution 
testing apparatus II (paddle method) using 500 
ml of phosphate buffer (pH = 6.8) as a 
dissolution medium at 50 rpm; the temperature 
was kept constant at 37 ± 0.1 °C. Aliquots (5 ml) 
were withdrawn at pre-determined time intervals 
of 5, 10, 15, 30, 45, 60, 70, and 90 mins with 
replenished on each occasion with the same 
volume of dissolution fluid [12]. The absorbance 
of the drug in the samples was measured 
spectrophotometrically at 238 nm. The mean of 





Preparation of simvastatin orodispersible 
tablets 
 
Simvastatin orodispersible tablets were prepared 
using the novel superdisintegrants Emcosoy, and 
Polacrillin potassium by direct compression. 
According to the composition shown in Table 1, 
eight orodispersible formulations of simvastatin 
were prepared. Preweighed amount of the 
prepared solid dispersion equivalent to 10 mg 
simvastatin was mixed with all ingredients in a 
cubic mixer by geometrical dilution for 10 min. 
The mixture was directly compressed on a flat 
10-mm punch/die set of a tableting machine 
(Erweka Tablet Press-Type EK0) without 
granulation.  
 





Twenty tablets were randomly selected from 
each formulation and separately weighed 
(Shimadzu digital balance BL-220H) and their 





Ten tablets from each formulation were randomly 
taken and their diameter and thickness were 
measured at two different positions with a 




For the content uniformity test, ten tablets were 
weighed and pulverized to a fine powder, a 
quantity of powder equivalent to single dosage 
unit was extracted with methanol and simvastatin  
     Table 1: Composition of simvastatin orodispersible tablets 
 
Formula 
Ingredient (mg)   
F1 F2 F3 F4 F5 F6 F7 F8 
Simvastatin SD   170 170 170 170 170 170 170 170 
Emcosoy   0 15 30 45 0 15 30 45 
Polacrillin Potassium   45 30 15 0 45 30 15 0 
Pullulan   75 75 75 75 0 0 0 0 
Mannitol   0 0 0 0 75 75 75 75 
Aerosil   3 3 3 3 3 3 3 3 
Saccharin Sodium   3 3 3 3 3 3 3 3 
Magnesium stearate   3 3 3 3 3 3 3 3 
Talc   1 1 1 1 1 1 1 1 
Total    300 300 300 300 300 300 300 300 
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content was determined as previously mentioned 





The average breaking strength (kg/cm2) of ten 
tablets of each formula was determined by 




Ten tablets from each batch were accurately 
weighed and placed in the drum of a friabilator 
(Erweka, Germany) rotated at 25 rpm for a 
period of 4 min, then dusted, and reweighed. The 
percentage weight loss was calculated and taken 
as a measure of friability. 
 
In vitro dispersion time 
 
Ten tablets were separately placed in a 25 ml 
beaker containing 10 ml of distilled water (pH = 
6.8) at 37 ± 0.5ºC and the time required for 
complete dispersion was determined. 
 
Wetting time and water absorption ratio [13]. 
 
Tablets were separately weighed (Wa) and 
carefully placed onto the surface of a piece of 
tissue paper twice folded in a 5 cm diameter petri 
dish containing 6 ml of aqueous amaranth 
solution. The time (in seconds) for complete 
wetting (water reaches the upper surface of the 
tablet) was noted and recorded as the wetting 
time. The wetted tablet was carefully removed 
and reweighed (Wb). Water absorption ratio (R) 
through the tablet was then determined 
according to Eq 1.  
 
R= 100 x (Wb – Wa)/Wb ………………..……... (1) 
 
 In vitro release studies 
 
The drug release rate from the prepared 
orodispersible tablets was carried out in Erweka-
USP dissolution testing apparatus II (paddle 
method) following the same conditions applied to 
determine the drug release rate from the 
prepared solid dispersion.. For comparison T 




Statistical analysis was performed using SPSS 
version 18 software for Windows (SPSS, Inc., 
Chicago, IL). Differences among group means 
were analyzed for statistical significance using 
one-way ANOVA followed by the Tukey-Kramer 
Multiple Comparisons Test. Differences were 
considered significant at p < 0.05.  
   
     Table 2: Characteristics of the prepared solid dispersions 
 
Polymer D:P Code SKn D.C (%) Code SEv D.C (%) 
β-CD 1:1 F1a 2.254 97.2 F1b 4.523 98.5 
β-CD 1:2 F2a 4.686 96.4 F2b 6.312 97.1 
β-CD 1:3 F3a 5.714 97.2 F3b 7.324 98.1 
H-p-β-CD 1:1 F4a 4.333 98.1 F4b 6.314 98.1 
H-p-β-CD 1:2 F5a 5.954 98.2 F5b 8.943 98.2 
H-p-β-CD 1:3 F6a 6.826 97.6 F6b 9.645 97.1 
H-b-β-CD 1:1 F7a 6.113 96.6 F7b 9.876 98.2 
H-b-β-CD 1:2 F8a 9.223 98.2 F8b 12.324 97.6 
H-b-β-CD 1:3 F9a 10.114 97.3 F9b 13.107 99.4 
   
 
Kneading method Solvent evaporation 
Code Polymer D:P 
SKn D.C (%) SEv D.C (%) 
F1 β-CD 1:1 2.254 97.2 4.523 98.5 
F2 β-CD 1:2 4.686 96.4 6.312 97.1 
F3 β-CD 1:3 5.714 97.2 7.324 98.1 
F4 H-p-β-CD 1:1 4.333 98.1 6.314 98.1 
F5 H-p-β-CD 1:2 5.954 98.2 8.943 98.2 
F6 H-p-β-CD 1:3 6.826 97.6 9.645 97.1 
F7 H-b-β-CD 1:1 6.113 96.6 9.876 98.2 
F8 H-b-β-CD 1:2 9.223 98.2 12.324 97.6 
F9 H-b-β-CD 1:3 10.114 97.3 13.107 99.4 
SKn = solubility (µg/ml) for kneading method; SEv = solubility (µg/ml) for solvent evaporation method; *molar drug/polymer ratio; 
**drug content. 
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Effect of solid dispersion, polymer type, 
preparation method, and drug polymer ratio on 
the drug water solubility was studied and the 
results (Table 2) showed that the drug solubility 
was increased in all prepared solid dispersion 
mixtures, and the increment of drug solubility 
was proportional to the polymer concentration.  
 
Based on these results, simvastatin-hydroxy-
butyl-β-cyclodextrin solid dispersion prepared in 
1:2 drug: polymer ratio by solvent evaporation 
method was selected and subjected to further 
evaluation by DSC and FTIR, and for drug 




Figure 1 shows the DSC thermograms and FTIR 
spectra of simvastatin, H-b-β-CD, their physical 
mixture, and the prepared solid dispersion. 
Simvastatin shows a sharp endothermic melting 
peak at 138 °C. This peak was retained in the 
thermogram of the physical mixture with no 
appearance of new peaks, which means there 
was no incompatibility. In the solid dispersion 
themogram, the peak completely disappeared  
FTIR spectrum of simvastatin showed the main 
characteristic peaks at 3553 cm-1 (free O–H 
stretching vibrations); 3011, 2959, and 2872 cm-1 
(C–H stretching vibrations); and 1714 cm-1  
 
 
(a)     (b)   
 
Figure 1: (a) DSC thermaograms of (A) Simvastatin, 
(B) H-b-β-CD, (C) Physical mixture, (D) Solid 
dispersion; (b) FTIR spectra of (E) Simvastatin, (F) H-
b-β-CD/Simvastatin Physical mixture, (G) H-b-β-
CD/Simvastatin Solid dispersion.  
 
Drug content  
 
Results of drug content (Table 2) showed 
excellent loading capacity of the drug into the 
polymer matrix in the prepared solid dispersion 
independent of the polymer type and preparation 
method. The percentage drug content ranged 
from 96.4% to 99.4.  
Figure 2 shows the effect of cyclodextrin 
complexation on the release profiles of 
simvastatin from the prepared solid dispersion in 
different ratios. Results indicated that the 
release rate of simvastatin was significantly 
increased when dispersed in different 
cyclodextrin derivatives. Hydroxyl butyl 
derivative of cyclodextrin showed higher 
solubility than hydroxyl propyl derivative than 
cyclodextrin and the higher the polymer 
concentration in the prepared solid dispersion 
the faster the release rate occurred. 
 
Physicochemical properties of simvastatin 
orodispersible tablets 
 
The formulated tablets exhibited low weight 
variation (295 to 311 mg), drug content was 
between 98.32 – 101.37 % with low standard 
deviation values; the thickness of tablets varied 
from 2.2 to 2.4 mm. All formulations showed 
good mechanical resistance and breaking 
strength, while friability values were all < 1 % and 
varied between 0.213 - 0.465 %; hardness was 
in the range of 3.78 - 2.41 Kg/cm2 that lies within 
acceptable USP limits.  
 
The behavior of the prepared simvastatin 
orodispersible tablets in contact with water was 
studied by measuring wetting time, water 
sorption rate, in vitro dispersion time, and drug 
release rate from the tablets. Results are 




Simvastatin solid dispersion with hydroxyl butyl 
derivative of cyclodextrin showed higher solubility 
more than solid dispersion prepared with 
hydroxyl propyl derivative  and by cyclodextrin; 
The solid dispersion made by solvent 
evaporation method was superior to that 
prepared by kneading method. Hydroxy-butyl-β-
CD has surfactant-like properties owing to the 
hydrophilicity of its exterior surface which can 
lower the interfacial tension between poorly 
soluble drugs and the dissolution medium, 
resulting in a higher dissolution rate. β-CD with 
longer C-2 substituted group increased the 
hydrophilic character of the molecule and hence 
stronger surfactant action on drug/water contact 
angle was expected and higher dissolution rates  
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Figure 2: (A) Dissolution Profiles of the Pure simvastatin (◊), and from solid dispersions F7a (□), F8a (∆), F9a 
(○), F7b (■), F8b (▲), F9b (●); (B) Dissolution Profiles of the Prepared Orodispersible Tablet Formulations F1 ( - 
), F2 (■), F3 (▲), F4 (○), F5 (x), F6 (●), F7 (∆), F8 (□). 
 
   Table 3: Hydrophilic properties of simvastatin orodispersible tablets 
 








(%) in 5 min 
T50% 
(min.) T90% (min.) 
F1 40 ±4 70±5 68 ±2 30.2 ±3.21 11.23 27.34 
F2 35 ±3 65±3 50 ±2 25.3 ±2.12 13.76 24.54 
F3 24 ±3 76±2 41 ±3 54.7 ±3.53 4.27 11.34 
F4 20 ±2 82±3 35 ±4 60.5 ±2.32 3.75 9.75 
F5 56 ±3 46±2 77 ±2 31.3 ±4.13 11.56 29.24 
F6 50 ±4 51±3 75 ±2 33.4 ±4.23 10.54 20.65 
F7 42 ±4 57±1 64 ±3 38.3 ±2.93 8.23 18.43 
F8 37 ±3 62±2 56 ±2 48.9 ±4.23 5.57 13.35 
 
 
obtained. This explained the better solubility 
results of hydroxy-butylated β-CD than hydroxy 
propylated form [14]. 
 
Despite the fact that formula F9 prepared in 1:3 
drug/polymer ratio showed a higher solubility 
results, it was not selected for further study 
because the tablet weight in orodispersible 
formulation is a critical factor and restricted to a 
certain degree that not affect patient compliance 
and due to the formula F9 contain polymer in 
large amount so the amount of solid dispersion 
require to be incorporated in the tablet will be 
very large). 
 
In the DSC thermograms of solid dispersion, the 
peak completely disappeared indicating 
formation of solid dispersion and conversion of 
drug from crystalline to amorphous state. The 
disappearance of the drug melting peak also 
indicates that it penetrated into H-b-β-CD cavity 
replacing the water molecule [15]. 
 
The main characteristic peaks of simvastatin 
FTIR spectrum were retained in physical 
mixtures and SD, which clearly indicate that no 
chemical interaction occurred between pure drug 
and polymer in SD 
 
Simvastatin orodispersible tablets were prepared 
using the novel superdisintegrants Emcosoy, and 
Polacrillin potassium either alone or in 
combinations by direct compression. 
 
Emcosoy is natural soy polysaccarides, that have 
no starch or any sugar and contains 75 % dietary 
fiber. It is an ideal choice for low calorie and 
diabetic applications. In tablet manufacture; it 
had evidence of a fast and efficient disintegration 
power over an extended range of hardness 
values with improved dissolution characteristics 
[16]. 
 
Polacrillin Potassium is a derivative of 
crosslinked polymer of polycarboxylic acids. In 
contact with aqueous media; it shows a very high 
swelling power leading to a very fast 
disintegration without the formation of lumps. It 
imparts excellent strength to the tablet and has 
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anti-adherent characteristics that prevent sticking 
to the dyes and punch [17]. 
 
Water insoluble diluents such as microcrystalline 
cellulose and dicalcium phosphate were 
excluded from the preparation of orodispersible 
formulae due to the expected objectionable 
feeling of grittiness in the mouth. Soluble 
diluents, mannitol and Pullulan were selected as 
diluent. Pullulan, a linear glucosic polysaccharide 
with high water solubility is an edible, bland 
and tasteless polymer[18]. 
 
All the deve;oped simvastatin orodispersible 
formulations were acceptable and their behavior 
in contact with water was very good as indicated 
by the short wetting time, rapid water sorption 
rate and a short disintegration time. 
 
Wetting time is an indication of the hydrophilicity 
of the inner structure of the tablet and excepients 
used. Thus wetting time of a dosage form is 
related to contact angle. The lower the wetting 
time the quicker is the tablet disintegration [19]. 
The disintegration time of orodispersible tablets 
ranges from 5 – 30 s [20]. 
 
The dissolution profiles of different simvastatin 
orodispersible tablet formulae indicate a higher, 
faster, and maximum drug release from formula 
F4 and F3 followed by F8 and F7, where the 
percentage of drug release reached 100%, 
99.1%, 96.2% and 95.8% respectively after 20 
min. These results correlate with wetting and 
disintegration time data, and it reflects the effect 
of different formulation factors on tablet 
hydrophilicity. 
 
Further analysis of dissolution data indicate that 
batches F4, F3, and F8 shows that initial rapid 
drug release reached 60.5, 54.7, and 48.9 %, 
respectively after 5 min. This can be attributed to 
the higher hydrophilic properties and stronger 
swelling power of Emcosoy in these formulations, 
while the presence of the very hydrophilic 
Pullulan as diluent in batches F4 and F3 resulted 
in a higher initial drug release. The release rate 
was also dependent on the Pullulan proportion in 
both formulations. F8 contained mannitol as 
diluent showed least initial drug release due to its 
lower hydropholicity than pullulan.  
 
Statistical analysis of T90 was made to test for 
the significance of the detected difference 
between the prepared tablet formulations. The 
results show that the detected difference was 
significant between all prepared formulations 
except that between F1, F2, and F5 and also that 
between F3, F4, and F8 as well as that between 
F6 and F7. These results indicate that 
superdisintegrant type is the main factor that 
affects the release of drug from the prepared 
tablets rather than its ingredient ratio, and that 





H-b-β-CD is an efficient polymer to prepare 
simvastatin solid dispersion and the preparation 
method together with the drug polymer ratio are 
critical and significantly affect drug solubility 
release. The use of suitable superdisintegrants 
for the preparation of fast-dissolving tablets is 
critical, as evidenced by the effect of Emcosoy. 
Similarly, the use of a suitable diluent such as 
Pullulan promotes water contact which is bery 
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